Hsp90 has emerged as an important target for diagnosis or therapy of prostate cancer. In this study, we labeled Hsp90 alpha specific monoclonal antibody (Hsp90 alpha-mAb) with radioiodine (NaI)-I-131 and investigated its potential usage in diagnostic imaging of prostate tumor in xenograft mice...
For instance, the blockade of free IgE by omalizumab (anti-IgE monoclonal antibody) showed some clinical benefit in AD patients with poor response to traditional therapy (Wang et al. 2016). In addition, clinical evidence suggests that targeting IgE antibodies by immunoadsorption seems to be an ...
摘要 目的:探索抗HSP90单克隆抗体28C10通过靶向肿瘤干细胞促进顺铂(cisplatin,DDP)对人胃癌细胞PAMC82恶性生物学行为的抑制效果及其可能的作用机制。方法:28C10单独或与DDP联合处理人胃癌细胞PAM...展开更多 Objective:To explore the promotive effect of anti-HSP90 monoclonal antibody mAb 28C10 on Cisplatin(DDP)...
Therefore, we discovered a novel HSP90 inhibitor HCP1 that had better biological activity and provided us a useful tool to explore the underlying mechanism of lung cancer therapy. Graphical abstract Download: Download high-res image (147KB) Download: Download full-size image...
EMT events are correlated with metastatic recurrence following surgery (18, 24), and have recently been observed concurrently following androgen withdrawal therapy (25). Therefore, the ability to identify primary tumor cells with an increased propensity to undergo EMT-like events would improve ...
为了进行这些实验,在有BuoPORTERTM蛋白转染试剂(Gene Therapy Systems,San Diego,CA)存在的情况下,向HeLa细胞(2×105)中添加5μg抗存活蛋白mAb 8E2或58或小鼠IgG在OptiMEMTM(Invitrogen,Carlsbad,CA)中的溶液。4小时后,向细胞中添加100μg/ml环己酰亚胺,用Western印迹分析90分钟内(第0,30,60和90分钟时)的存活...
Utilizing the TIDE and TISMO systems, an analysis was performed to predict the efficacy of Immune Checkpoint Inhibitors (ICIs) therapy. Finally, a series of small-molecule drugs, possessing promising therapeutic potential, were forecast using the GSCA platform.Expression of PD-L2 was pervasive in ...
Ying, W.et al.Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.Mol. Cancer Ther.11, 475–484 (2012). PubMedGoogle Scholar Scarneo, S. A.et al.Pharmacological inhibition of TAK1, with the selective...
Drug resistance and tumor heterogeneity are formidable challenges in cancer medicine, which is particularly relevant for KRAS-mutant cancers, the epitome of malignant tumors recalcitrant to targeted therapy efforts and first-line chemotherapy. In this st
Prognosis and overall survival of patients diagnosed with cancer has dramatically improved in the last decades. However, high initial cancer treatment response rates are often followed by the development of resistance to the therapy and eventual recurrence of the disease. Oftentimes, the recurring tumor...